Pharma Licensing Licensing momentum with Tris Digital Health and PepsiCo Greenhouse shows openness to pharma and consumer health partnerships, creating a route for co development or licensing of the eye movement biomarker platform for ADHD, Alzheimer's and cognitive health applications.

Clinical Adoption Solutions have been used for years in leading clinics, indicating real world validation and potential for pilots with neurology, psychiatry and geriatrics centers, with a small team that can offer targeted services and scalable pilots.

Digital Therapeutics The ADHD therapy app and diagnostic software demonstrate capability as a digital therapeutics platform, presenting opportunities to expand offerings, license to clinics and payers, and provide data analytics and remote monitoring.

IP Advantage Worldwide patent protection for eye movement cognitive vergence provides a defensible technology moat and potential licensing leverage with device manufacturers, EHRs and digital health platforms.

Growth Partners Funding history and strategic partnerships suggest opportunities for joint ventures or funded pilots with healthcare and consumer health players, accelerating market entry in Europe and beyond.